The rise of Viagra and its influence on the pharmaceutical landscape presents a complex question for investors. While the initial sales data were astounding, the exclusivity has expired, leading to a deluge of off-brand alternatives that are eroding earnings. In addition, the market is facing challenges related to aging trends and shifting healt… Read More